The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ex ante budget impact analysis (BIA) of PD-1 inhibitor toripalimab plus gemcitabine-cisplatin (T+GC) versus a simulated pembrolizumab regimen in first line (1L) treatment of recurrent or metastatic nasopharyngeal cancer (rmNPC).
 
Ivo Abraham
Employment - Matrix45; Matrix45 (I)
Leadership - Matrix45 (I)
Stock and Other Ownership Interests - Matrix45; Matrix45 (I)
Consulting or Advisory Role - Matrix45 (I)
Speakers' Bureau - Matrix45
Research Funding - Matrix45; Matrix45 (I)
Patents, Royalties, Other Intellectual Property - Book royalties
(OPTIONAL) Uncompensated Relationships - Matrix45
 
Robert B. Geller
Employment - Coherus Biosciences; Coherus Biosciences
Stock and Other Ownership Interests - Coherus Biosciences
 
Paul D. Walden
Employment - Coherus Biosciences
Stock and Other Ownership Interests - Coherus Biosciences
 
Karen MacDonald
Employment - Matrix45; Matrix45 (I)
Leadership - Matrix45; Matrix45 (I)
Stock and Other Ownership Interests - Matrix45; Matrix45 (I)
Consulting or Advisory Role - Matrix45; Matrix45 (I)
Speakers' Bureau - Matrix45 (Inst)
Research Funding - Matrix45; Matrix45 (I)
Patents, Royalties, Other Intellectual Property - Book royalties (I)